Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antisense oligonucleotide |
| gptkbp:approvedBy |
gptkb:European_Union
|
| gptkbp:ATCCode |
none
|
| gptkbp:brand |
gptkb:Waylivra
|
| gptkbp:CASNumber |
1395907-82-2
|
| gptkbp:compatibleWith |
gptkb:United_States
|
| gptkbp:developer |
gptkb:Ionis_Pharmaceuticals
|
| gptkbp:hasMolecularFormula |
C418H522N176O124P22S22
|
| https://www.w3.org/2000/01/rdf-schema#label |
volanesorsen
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits apolipoprotein C-III synthesis
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
thrombocytopenia
injection site reactions |
| gptkbp:target |
APOC3 mRNA
|
| gptkbp:usedFor |
gptkb:familial_chylomicronemia_syndrome
|
| gptkbp:bfsParent |
gptkb:FCS_syndrome
gptkb:familial_chylomicronemia_syndrome gptkb:Waylivra |
| gptkbp:bfsLayer |
7
|